Literature DB >> 29712820

Denosumab for bone lesions in multiple myeloma - what is its value?

Daniel A Goldstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29712820      PMCID： PMC5927995          DOI： 10.3324/haematol.2017.185264

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

Review 1.  From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.

Authors:  Kanwal Pratap Singh Raghav; Sminil Mahajan; James C Yao; Brian P Hobbs; Donald A Berry; Rebecca D Pentz; Alda Tam; Waun K Hong; Lee M Ellis; James Abbruzzese; Michael J Overman
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

2.  American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

Authors:  Lee M Ellis; David S Bernstein; Emile E Voest; Jordan D Berlin; Daniel Sargent; Patricia Cortazar; Elizabeth Garrett-Mayer; Roy S Herbst; Rogerio C Lilenbaum; Camelia Sima; Alan P Venook; Mithat Gonen; Richard L Schilsky; Neal J Meropol; Lowell E Schnipper
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

Review 4.  Denosumab and bisphosphonates: different mechanisms of action and effects.

Authors:  Roland Baron; Serge Ferrari; R Graham G Russell
Journal:  Bone       Date:  2010-12-09       Impact factor: 4.398

5.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

6.  Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.

Authors:  Sant Chawla; Robert Henshaw; Leanne Seeger; Edwin Choy; Jean-Yves Blay; Stefano Ferrari; Judith Kroep; Robert Grimer; Peter Reichardt; Piotr Rutkowski; Scott Schuetze; Keith Skubitz; Arthur Staddon; David Thomas; Yi Qian; Ira Jacobs
Journal:  Lancet Oncol       Date:  2013-07-16       Impact factor: 41.316

7.  Denosumab in postmenopausal women with low bone mineral density.

Authors:  Michael R McClung; E Michael Lewiecki; Stanley B Cohen; Michael A Bolognese; Grattan C Woodson; Alfred H Moffett; Munro Peacock; Paul D Miller; Samuel N Lederman; Charles H Chesnut; Douglas Lain; Alan J Kivitz; Donna L Holloway; Charlie Zhang; Mark C Peterson; Pirow J Bekker
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

8.  Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.

Authors:  Gabriel N Hortobagyi; Catherine Van Poznak; W Graydon Harker; William J Gradishar; Helen Chew; Shaker R Dakhil; Barbara B Haley; Nicholas Sauter; Ramon Mohanlal; Ming Zheng; Allan Lipton
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777
  8 in total
  5 in total

1.  RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway.

Authors:  Mineon Park; Yong Jin Cho; Bora Kim; Young Jong Ko; Yuria Jang; Yeon Hee Moon; Hoon Hyun; Wonbong Lim
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

2.  Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.

Authors:  Sara Jane Cromer; Kristin M D'Silva; Elaine W Yu; Joan Landon; Rishi J Desai; Seoyoung C Kim
Journal:  J Gen Intern Med       Date:  2021-06-07       Impact factor: 6.473

Review 3.  Bone Marrow-Derived Mesenchymal Stromal Cells: A Novel Target to Optimize Hematopoietic Stem Cell Transplantation Protocols in Hematological Malignancies and Rare Genetic Disorders.

Authors:  Stefania Crippa; Ludovica Santi; Roberto Bosotti; Giulia Porro; Maria Ester Bernardo
Journal:  J Clin Med       Date:  2019-12-18       Impact factor: 4.241

Review 4.  Management of Myeloma Bone Lesions.

Authors:  Jeng-Shiun Du; Chia-Hung Yen; Chin-Mu Hsu; Hui-Hua Hsiao
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

Review 5.  Pathogenesis and Treatment of Myeloma-Related Bone Disease.

Authors:  Yuh-Ching Gau; Tsung-Jang Yeh; Chin-Mu Hsu; Samuel Yien Hsiao; Hui-Hua Hsiao
Journal:  Int J Mol Sci       Date:  2022-03-14       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.